tested bexarotene as a potential b-amyloid-lowering drug for Alzheimer's disease (AD). We were not able to reproduce the described effects in several animal models. Drug formulation appears very critical. Our data call for extreme caution when considering this compound for use in AD patients.
in beagle dogs did not affect Ab levels in cerebrospinal fluid (CSF) (Fig. 1C) . The drug reached high concentrations in plasma (Fig. 1D) .
We tested chronic oral bexarotene treatment (100 mg/kg per day for 19 days) in 10-monthold male hAPP/PS1 mice (3) and euthanized the mice 24 hours after the last dose. Plaque burden and plaque number in the right hemispheres (Fig. 2 , A to D) and soluble Ab in the left hemispheres was not altered (Fig. 2E ). ABCA1 levels were significantly up-regulated (Fig. 2F) , demonstrating target engagement. Changes in APP, APP-CTF fragments, or apoE levels were not observed. Thus, previously observed acute and chronic effects of bexarotene on brain Ab levels (2) were not reproduced.
We also tested cognitive status in chronically treated hAPP/PS1 mice. Although social recognition memory seemed improved after 14 days of treatment (Fig. 2 , G and H), exploratory tendency was generally reduced in treated versus untreated hAPP/PS1 and control wild-type mice (Fig. 2I) . Reanalyzing the recordings revealed a significant increase of grooming behavior in bexarotenetreated hAPP/PS1 mice (Fig. 2, J and K) . Skin irritation and itching appear to be common reactions in patients taking Targretin (4). In addition, bexarotene-treated mice showed significant weight loss, increased irritability during handling and oral gavage, and difficulty breathing, which indicate severe adverse effects of the treatment (Fig. 2,  M and N) . Those might interfere with the execution of behavioral tests. The retention test of the passive avoidance task showed longer step-through latency in the bexarotene-treated hAPP/PS1 mice ( Fig. 2L) , but, again, adverse effects of the treatment confound interpretation. Thus, although we cannot exclude an effect of bexarotene on memory, the adverse effects of the drug make a definitive conclusion impossible.
Bexarotene is insoluble in water, and we therefore used Captisol (Cydex Pharmaceuticals), a widely used formulation for hydrophobic drugs, and 2-Hydroxypropyl-b-cyclodextrin (HP-b-CD/ Tween), another b-cyclodextrine, for drug administration in mice and dogs, respectively. Cramer et al. wrote that they solubilized bexarotene in water (2), but we learned afterward that they actually used Targretin capsules. These capsules contain additional ingredients (5). Because Cramer et al. (2) used a different formulation (dimethyl sulfoxide and intraperitoneal injections) for their tissue bioavailability studies, we are not sure how to relate the different experiments published in (2) with regard to formulation and administration routes. The FDA filing mentions increased bexarotene uptake when the drug is taken together with highfat food (5); thus, differences in fat content of mouse chow might further confound these studies. Our data demonstrate that we had good brain penetration of the drug and ABCA1 target engagement, but no effects on Ab. We want to alert the field to this important issue. Given the toxicity of bexarotene, our study clearly strongly cautions against testing this drug in AD patients at this time. Band intensities given as fold intensity toward control. Each dot represents one mouse. ****P < 0.0001; unpaired Student's t test with Welch's correction. Social recognition memory was recovered in bexarotene-treated hAPP/PS1 as indicated by raw exploration data (G) and ratio data (H). Bexarotene-treated hAPP/PS1 displayed less exploration than wild-type control and control hAPP/PS1 mice [(G) and (I)] and spent significantly more time in total grooming (J) and maximum grooming sequence (K). In the passive avoidance (L), bexarotenetreated hAPP/PS1 mice showed significantly longer step-through latency during retention testing than control hAPP/PS1 mice. Body weight was monitored during the entire experiment (M and N). Wild-type control and control hAPP/PS1 mice showed no significant changes in weight during the experiment, whereas bexarotene-treated hAPP/PS1 mice displayed a sharp drop in body weight after 4 days of treatment (M). At the end of the experiment, bexarotene-treated hAPP/PS1 mice lost~10% of their initial weight (N). Data are expressed as means T SEMs. ###P < 0.001, significant within group exploration difference between S1 (familiar mouse) and S2 (novel mouse), Two-way repeated-measures analysis of variance (ANOVA) with Tukey test; *P < 0.05, **P < 0.01, ***P < 0.001, significant difference between groups, one-way-ANOVA with Tukey test.
